Advertisement
YOU ARE HERE: LAT HomeCollectionsBotox
IN THE NEWS

Botox

FEATURED ARTICLES
BUSINESS
August 3, 2011
Allergan, Inc., the maker of Botox, said second-quarter profit rose 2.7 percent and raised its earnings forecast on higher sales of the wrinkle smoother and breast implants. Net income increased to $246.6 million, or 79 cents a share, from $240.1 million, or 78 cents, a year earlier, the Irvine, California-based company said today in a statement. Earnings, excluding some items, were 96 cents a share, topping the average estimate of 95 cents from 21 analysts surveyed by Bloomberg.
ARTICLES BY DATE
BUSINESS
April 23, 2014 | By Stuart Pfeifer
Takeover target Allergan Inc., the company that makes Botox, has adopted a "poison pill" defense intended to delay a buyout by Canadian company Valeant Pharmaceuticals International Inc. and activist investor Bill Ackman. The Irvine company's "stockholder rights plan" allows existing shareholders to buy Allergan stock at a steep discount if any single investor acquires more than 10% of its shares. That would drive down the value of the major investors' shares, making it unlikely that anyone would acquire that much stock.
Advertisement
NEWS
October 15, 2010
The makers of the miracle toxin that erases frown lines by paralyzing facial muscles won the Food and Drug Administration's blessing on Friday to market Botox for the prevention of chronic migraine headaches. The FDA's decision expands the potential market for Botox, which burst upon the American cosmetic scene in the late 1980s, to 12% of the U.S. population -- the proportion of Americans thought to suffer from the throbbing, pulsating pain of migraine headaches . The agency's approval Friday allows Allergan Inc., which produces a purified version of the botulinum toxin, to advertise to consumers and promote to doctors the use of Botox for chronic migraine, defined as migraine headaches that occur more than 14 days per month.
BUSINESS
April 22, 2014 | By Stuart Pfeifer
Canadian company Valeant Pharmaceuticals International Inc. and activist investor Bill Ackman moved forward with their plans to acquire Botox maker Allergan Inc., offering shareholders about $46 billion and touching off what could be a contentious fight. Several industry analysts said they expect Allergan to reject the offer as too low, and said a fierce boardroom battle may be on the horizon. An issue certain to alarm Allergan is Valient's announced plans to slash research and development spending at the Irvine company.
BUSINESS
September 11, 2013 | By Stuart Pfeifer
It's getting easier for Baby Boomers to hide their years. Federal regulators for the first time have approved Botox injections to temporarily ease the appearance of crow's feet. The Food and Drug Administration on Wednesday approved the drug, made by Irvine-based Allergan Inc., to treat wrinkles that form on the outside edge of the eyes. The decision comes 11 years after the FDA approved Botox for the temporary improvement of wrinkles between the eyebrows, known as frown lines.
ENTERTAINMENT
April 12, 2013 | By Nardine Saad
Hey, Gwyneth Paltrow, Joan Rivers isn't offended by your Botox gibe. Speaking to Harper's Bazaar , Paltrow, 40, an organic products and fitness advocate, recently said that there was a very specific reason she's staying away from one cosmetic procedure. And it happened to be the host of E!'s "Fashion Police. " "I would be scared to go under the knife, but you know, talk to me when I'm 50. I'll try anything," Paltrow said. "Except I won't do Botox again, because I looked crazy.
BUSINESS
September 12, 2008 | From the Associated Press
Botox, the botulism-based drug that has wiped wrinkles from the faces of millions, may be approved for another use: stopping headaches. Drug maker Allergan Inc. said Thursday that it had new evidence that its injectable drug could help relieve migraine headaches. Based on preliminary results from two company-funded studies, Allergan said it would ask the Food and Drug Administration to approve Botox for chronic migraine next year. The FDA approved Botox to smooth wrinkles and age lines in 2002, and it has grown into a blockbuster product for Irvine-based Allergan, with $2.1 billion in sales last year.
BUSINESS
October 3, 2009 | Nathan Olivarez-Giles
Allergan Inc., maker of wrinkle treatment Botox, is challenging the government's ban on marketing off-label uses for pharmaceuticals. In a lawsuit filed Thursday, the Irvine company argued that it should be allowed to give doctors information about using Botox for treatments not approved by the Food and Drug Administration, including bladder problems, muscle spasms and headaches. Botox is approved by the FDA for use cosmetically as a wrinkle treatment and medically for eye-muscle disorders, excessive underarm sweating and cervical dystonia in adults, which causes abnormal head positions and neck pain.
BUSINESS
March 5, 2008 | Lisa Girion, Times Staff Writer
The U.S. Department of Justice is looking at Allergan Inc.'s promotion of its blockbuster wrinkle drug Botox for medical uses, but investors didn't seem too worried about the news Tuesday. Allergan shares closed at $57.38, down $1.28 or 2.2% on word that the Irvine company received a subpoena from the U.S. Attorney's Office for the Northern District of Georgia demanding documents regarding its promotional and educational practices involving the use of the botulinum toxin-based drug for medical problems.
BUSINESS
May 8, 2008 | From Times Wire Services
Allergan Inc.'s net income more than doubled in the first quarter as sales accelerated outside the U.S. for the wrinkle remover Botox. Demand cooled in the U.S., and the company blamed the economy. Net income increased to $111.4 million, or 36 cents a share, from $43.8 million, or 14 cents, a year earlier, the company said. Revenue grew 23% to $1.08 billion, bolstered by converting overseas sales in other currencies to the dollar. Irvine-based Allergan sells cosmetic and medical products including breast implants, surgical devices to remedy obesity and a treatment for overactive bladders.
BUSINESS
April 21, 2014 | By Stuart Pfeifer
Activist investor Bill Ackman is partnering with Valeant Pharmaceuticals in an attempt to buy Orange County pharmaceutical company Allergan Inc., which sells the popular wrinkle treatment Botox. Ackman's Pershing Square Capital Management said in a public filing on Monday that it was partnering with Valeant to acquire shares of Allergan. Pershing Square and Valeant agreed to the partnership on Feb. 25, Ackman said in a filing with the Securities and Exchange Commission. Valeant said in a statement that it believed a partnership with Allergan would be best for both companies.
HOME & GARDEN
November 2, 2013 | Chris Erskine
Not so much a typical candidate for Botox, except that I have a face like a garden glove - sun-baked and ripped by boot and fist. If Levi Strauss made faces, I'd be a 42 regular. And stone-washed. Don't mean to brag, that's just the face I have. Genetics has a lot to do with it. Mom (a princess) first met Dad (a warlock) in a saloon one evening, and one thing led to another - an off-hand remark, some curly fries, a whiskey twinkle in her eye. In this case, love had nothing to do with it - it was raw, rampant monkey lust.
BUSINESS
September 11, 2013 | By Stuart Pfeifer
It's getting easier for Baby Boomers to hide their years. Federal regulators for the first time have approved Botox injections to temporarily ease the appearance of crow's feet. The Food and Drug Administration on Wednesday approved the drug, made by Irvine-based Allergan Inc., to treat wrinkles that form on the outside edge of the eyes. The decision comes 11 years after the FDA approved Botox for the temporary improvement of wrinkles between the eyebrows, known as frown lines.
ENTERTAINMENT
April 12, 2013 | By Nardine Saad
Hey, Gwyneth Paltrow, Joan Rivers isn't offended by your Botox gibe. Speaking to Harper's Bazaar , Paltrow, 40, an organic products and fitness advocate, recently said that there was a very specific reason she's staying away from one cosmetic procedure. And it happened to be the host of E!'s "Fashion Police. " "I would be scared to go under the knife, but you know, talk to me when I'm 50. I'll try anything," Paltrow said. "Except I won't do Botox again, because I looked crazy.
ENTERTAINMENT
April 11, 2013 | By Nardine Saad
Gwyneth Paltrow at 40 is very different than Gwyneth Paltrow at, say, 25 or 30. The award-winning actress who's made a name for herself beyond Hollywood because of her fit lifestyle and cookbooks is opening up about what keeps her going. "I'm at quite a pivotal point, she says in Harper's Bazaar's May issue. "Do I want to go back more into films? Do I want another child? Do I want to move back to the States? You can call me a lot of things, but you can't call me complacent!" Harper's writer Sarah Bailey credits Paltrow's landmark birthday to her "searing stock-taking," later adding that "there's something refreshingly frank and fearless about this new fifth-decade Gwyneth.
BUSINESS
March 3, 2013 | By Stuart Pfeifer, Los Angeles Times
The company: Allergan Inc. Headquarters: Irvine Ticker: AGN Employees: 10,800 Leadership: David E.I. Pyott, chief executive since 1998 Revenue: $5.8 billion in 2012 Net income: $1.1 billion in 2012 Stock price: $108.60 at Friday's close 52-week range: $81.28 to $109.31 P/E ratio: 22.8 based on 2013 estimated earnings Annual dividend: 5 cents, a current yield of about...
HEALTH
May 31, 2010 | By Siri Carpenter, Special to the Los Angeles Times
Botox may be famous for erasing frown lines, but it also may disrupt an important chain of communication between the face and the brain. Not only do our facial expressions reflect our emotional ups and downs, they appear to send crucial feedback to our brain, suggests a growing body of research. Without that full feedback loop, our ability to understand — and be understood — might be constrained. In a recent study of women undergoing cosmetic treatment with Botox, researchers found that the treatment, which blocks facial nerve impulses, seemed to slow the ability to comprehend emotional language.
NEWS
June 21, 2011 | By Marissa Cevallos, HealthKey / For the Booster Shots blog
Botox has been the reigning, if unofficial, monarch of cosmetic procedures for nearly a decade. But its claim to the beauty throne is being rattled this week by a study in which patients thought another brand of botulinum toxin, the Botox competitor Dysport, smoothed their “crow’s feet” wrinkles a bit better. In a randomized, double-blind face-off funded by the makers of Dysport, patients received injections of Botox on one side of the face and injections of Dysport on the other.
Los Angeles Times Articles
|